Simple oral "cabbage price" for "oval cancer patients"

Simple oral "cabbage price" for "oval cancer patients"

August 10, 2018 Source: Nanfang Daily

Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];

In patients with advanced ovarian cancer, once they have developed resistance to platinum-based chemotherapy drugs, they are basically equivalent to being sentenced to “death penalty” and there is no effective treatment. Today, this part of the patient has new hopes!

Recently, the team of Professor Huang Xin and Dr. Lan Chunyan from the Cancer Center of Sun Yat-sen University published the latest research results online in the top-ranking oncology magazine Lancet Oncology. A new all-oral drug treatment program is not only simple, but also effective. Significant, and low toxic side effects, patients can be treated in the clinic.

It is understood that this is the first time that the clinical research results led by gynecologic oncologists in mainland China have been published in the journal, and the results are expected to rewrite the guidelines for the treatment of clinical drug-resistant ovarian cancer.

Innovative joint targeted therapy

Anti-angiogenic drugs are a class of tumor-targeting drugs that inhibit tumor growth by inhibiting neovascularization around the tumor and cutting off the nutrition of the tumor. According to Huang Xin, some clinical studies in recent years have shown that anti-angiogenic drugs combined with chemotherapeutic drugs can effectively improve the prognosis of patients with platinum-resistant ovarian cancer.

One study confirmed that compared with chemotherapy alone, the anti-angiogenic drug bevacizumab combined with chemotherapy increased the median progression-free survival of platinum-resistant patients from 3.4 months to 6.7 months.

In another study, oral anti-angiogenic drug pazopanib plus paclitaxel weekly treatment also increased the median progression-free survival of platinum-resistant patients from 3.5 months to 6.3 months.

However, most targeted therapies require regular intravenous and hospitalization, which is inconvenient and costly. In addition, many new targeted drug treatments have not yet been listed in mainland China.

Professor Huang Xin and Professor Lan Chunyan turned their attention to the new class of domestic drug apatinib.

Most patients have significantly reduced tumors

Apatinib is a new generation of small molecule anti-angiogenic targeted drugs independently developed by China. It was approved for marketing in 2014, and its anti-tumor effect has been confirmed in many clinical studies of gastrointestinal cancer.

In the choice of chemotherapy drugs, the team chose etoposide, which is the simple and cost-effective effective drug for the treatment of recurrent ovarian cancer, a box of only 125 yuan, a box for each course of treatment.

Huang Xin, Lan Chunyan and Huang Huiqiang, a professor of internal medicine at the Zhongda Cancer Center, decided to boldly try a simple oral treatment with apatinib and etoposide. "The combination of the two can play a synergistic role, and there is no obvious toxicity stack, suitable for long-term palliative treatment of relapsed and refractory ovarian cancer."

In August 2016, the Phase II clinical study was officially launched, and 35 patients with platinum-resistant epithelial ovarian cancer were successfully enrolled in only 12 months. The patient took two drugs a day, all in the outpatient treatment, examination and follow-up.

The results of the study are encouraging. After the treatment of this program, 19 of the 35 patients were significantly reduced by more than 30%, the objective effective rate was 54.3%, and the control rate was 85.7%.

The median progression-free survival of patients with ovarian cancer was 8.1 months. “The objective and effective survival rate of the joint program is higher than the existing international consensus treatment plan.”

The monthly treatment fee is more than 8,200 yuan

"Only 35 cases of sample size, the results of the study can be published in the top cancer oncology "Lancet · Oncology", showing that this new treatment program is indeed highlights, has been highly recognized internationally." Huang Huiqiang said.

Huang Xin introduced that this program can greatly reduce the burden on patients, so it is very suitable for patients with refractory recurrent ovarian cancer as a common treatment, especially suitable for clinical application in developing countries such as China.

According to reports, new targeted drugs for advanced ovarian cancer are relatively expensive, a treatment cost of about 20,000 to 50,000 yuan, and this new combined chemotherapy program costs more than 8,200 yuan per month, and 80% of them can be reimbursed. And save on hospital expenses. Huang Huiqiang described this new targeted treatment program as “cabbage price”.

In addition, because this program can be taken orally in the clinic, the adverse reactions are easily tolerated and adjusted, which can effectively improve the compliance of patients' treatment and significantly improve the quality of life of patients.

Lan Chunyan said that the next step will be to expand the sample size to start the phase III clinical study, and compare the results with internationally recognized standard treatment plans for further in-depth research.

Huang Xin revealed that it is expected that the third phase of the study will recruit more than 100 patients as subjects, and the subjects will receive the drug free of charge. "Our results are expected to rewrite the guidelines for the treatment of clinical drug-resistant ovarian cancer for the benefit of the majority of patients." (Reporter Li Xiuting Intern Xie Wei correspondent Yu Guangyu Yang Sen)

Fresh Cut Shredded Auricularia auricula

Fresh Cut Shredded Auricularia Auricula,Shredded Auricularia Auricula,Dried Wood Ear Shreds,Jelly Ear

Guangyun Agricultural Biotechnology (Jiangsu) Co., Ltd , https://www.7-mushrooms.com